These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16870658)

  • 1. An oral selective M3 cholinergic receptor antagonist in COPD.
    Lu S; Parekh DD; Kuznetsova O; Green SA; Tozzi CA; Reiss TF
    Eur Respir J; 2006 Oct; 28(4):772-80. PubMed ID: 16870658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors].
    Abad Santos F; Novalbos J; Gallego Sandín S; Gálvez Múgica MA
    An Med Interna; 2003 Apr; 20(4):201-5. PubMed ID: 12768836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease.
    Li X; Obeidat M; Zhou G; Leung JM; Tashkin D; Wise R; Connett J; Joubert P; Bossé Y; van den Berge M; Brandsma CA; Nickle DC; Hao K; Paré PD; Sin DD
    EBioMedicine; 2017 May; 19():139-145. PubMed ID: 28461224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.
    Tashkin DP
    Expert Opin Drug Saf; 2015; 14(11):1759-72. PubMed ID: 26401729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic obstructive pulmonary disease.
    Yao W; Wang G; Zhu H; Sun Y; Zhao M
    Chin Med J (Engl); 2001 Jan; 114(1):80-3. PubMed ID: 11779443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical aspects of inhaled anticholinergic therapy.
    Campbell SC
    Respir Care; 2000 Jul; 45(7):864-7. PubMed ID: 10926384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of anticholinergics in the management of COPD.
    Scullion JE
    Int J Chron Obstruct Pulmon Dis; 2007; 2(1):33-40. PubMed ID: 18044064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
    Maltais F; Milot J
    Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
    Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF
    Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiotropium: a potential replacement for ipratropium in patients with COPD.
    Shukla VK
    Issues Emerg Health Technol; 2002 Jul; (35):1-4. PubMed ID: 12195603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
    Bateman E; Feldman G; Kilbride S; Brooks J; Mehta R; Harris S; Maden C; Crater G
    Clin Respir J; 2012 Oct; 6(4):248-57. PubMed ID: 22329914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticholinergic bronchodilators.
    Witek TJ
    Respir Care Clin N Am; 1999 Dec; 5(4):521-36. PubMed ID: 10565879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
    Vogelmeier C; Verkindre C; Cheung D; Galdiz JB; Güçlü SZ; Spangenthal S; Overend T; Henley M; Mizutani G; Zeldin RK
    Pulm Pharmacol Ther; 2010 Oct; 23(5):438-44. PubMed ID: 20416390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
    COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticholinergic agents in asthma and COPD.
    Gross NJ
    Eur J Pharmacol; 2006 Mar; 533(1-3):36-9. PubMed ID: 16488410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of inhaled anticholinergic agents in obstructive airway disease.
    Restrepo RD
    Respir Care; 2007 Jul; 52(7):833-51. PubMed ID: 17594728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tiotropium (Spiriva) - a long-acting inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease (COPD)].
    Beeh KM; Welte T; Buhl R
    Pneumologie; 2003 Sep; 57(9):519-25. PubMed ID: 13680472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
    Dahl R; Greefhorst LA; Nowak D; Nonikov V; Byrne AM; Thomson MH; Till D; Della Cioppa G;
    Am J Respir Crit Care Med; 2001 Sep; 164(5):778-84. PubMed ID: 11549532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticholinergic treatment in airways diseases.
    Flynn RA; Glynn DA; Kennedy MP
    Adv Ther; 2009 Oct; 26(10):908-19. PubMed ID: 19967500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.